Monomethyl auristatin E (MMAE) is conjugated to an anti-CD30 antibody in brentuximab vedotin, an ADC that is FDA-approved for Hodgkin lymphoma [143]. The gene discussed is TNFRSF8; the disease is Hodgkins lymphoma.